Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the possibility that generics could launch in the coming days.
Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help prevent HIV infection, thanks to positive data from a phase 1/2a trial.
Data and analytics firm GlobalData has tracked the market cap and performance of the top 25 pharma companies for the first quarter of this year – and there are some notable changes compared
As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and US private equity firm Platinum Equity over the sale of the
Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.